Rallybio Corporation (RLYB)

Rallybio Statistics

Total Valuation

Rallybio has a market cap or net worth of $27.34 million. The enterprise value is -$47.57 million.

Market Cap	27.34M
Enterprise Value	-47.57M

Important Dates

The next estimated earnings date is Thursday, May 8, 2025, before market open.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Rallybio has 41.49 million shares outstanding. The number of shares has increased by 8.55% in one year.

Current Share Class	41.49M
Shares Outstanding	41.49M
Shares Change (YoY)	+8.55%
Shares Change (QoQ)	+1.05%
Owned by Insiders (%)	4.06%
Owned by Institutions (%)	27.68%
Float	19.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	46.87
Forward PS	n/a
PB Ratio	0.39
P/TBV Ratio	0.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.55, with a Debt / Equity ratio of 0.00.

Current Ratio	9.55
Quick Ratio	9.18
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -68.90% and return on invested capital (ROIC) is -42.74%.

Return on Equity (ROE)	-68.90%
Return on Assets (ROA)	-39.29%
Return on Invested Capital (ROIC)	-42.74%
Return on Capital Employed (ROCE)	-94.19%
Revenue Per Employee	$13,907
Profits Per Employee	-$1.56M
Employee Count	43
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -64.19% in the last 52 weeks. The beta is -1.45, so Rallybio's price volatility has been lower than the market average.

Beta (5Y)	-1.45
52-Week Price Change	-64.19%
50-Day Moving Average	0.83
200-Day Moving Average	1.11
Relative Strength Index (RSI)	36.21
Average Volume (20 Days)	56,914

Short Selling Information

The latest short interest is 331,091, so 0.80% of the outstanding shares have been sold short.

Short Interest	331,091
Short Previous Month	350,193
Short % of Shares Out	0.80%
Short % of Float	1.69%
Short Ratio (days to cover)	5.03

Income Statement

In the last 12 months, Rallybio had revenue of $598,000 and -$66.97 million in losses. Loss per share was -$1.57.

Revenue	598,000
Gross Profit	6.10M
Operating Income	-66.70M
Pretax Income	-73.88M
Net Income	-66.97M
EBITDA	-66.56M
EBIT	-66.70M
Loss Per Share	-$1.57

Balance Sheet

The company has $75.14 million in cash and $230,000 in debt, giving a net cash position of $74.91 million or $1.81 per share.

Cash & Cash Equivalents	75.14M
Total Debt	230,000
Net Cash	74.91M
Net Cash Per Share	$1.81
Equity (Book Value)	70.82M
Book Value Per Share	1.71
Working Capital	70.04M

Cash Flow

In the last 12 months, operating cash flow was -$51.07 million and capital expenditures -$12,000, giving a free cash flow of -$51.08 million.

Operating Cash Flow	-51.07M
Capital Expenditures	-12,000
Free Cash Flow	-51.08M
FCF Per Share	-$1.23

Margins

Gross Margin	1,019.40%
Operating Margin	-11,153.85%
Pretax Margin	-11,199.50%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Rallybio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.55%
Shareholder Yield	-8.55%
Earnings Yield	-245.00%
FCF Yield	-186.85%

Analyst Forecast

The average price target for Rallybio is $9.75, which is 1,379.74% higher than the current price. The consensus rating is "Buy".

Price Target	$9.75
Price Target Difference	1,379.74%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Rallybio has an Altman Z-Score of -1.2 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.2
Piotroski F-Score	1